Moderna and Merck Report Positive Phase 3 Results for mRNA Cancer Vaccine

Moderna and Merck announced that their joint mRNA melanoma vaccine, combined with Keytruda, met its primary endpoints in a Phase 3 interim analysis. The results suggest the vaccine is effective in preventing recurrence, though experts caution that it is not a universal cure for all tumors.